Education
About Us
Working with TipRanks
Follow Us
Atyr Pharma Inc. (ATYR)
:ATYR
ATYR Analyst Ratings
Hold
2 Buy
7 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ATYR Stock 12 Month Forecast
Average Price Target
$6.92
▲(598.99% Upside)
| Highest Price Target$20.00 | Average Price Target$6.92 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$16→$1
Hold
1.01%
Upside
Downgraded
09/16/25
Wells Fargo
$25→$1
Hold
1.01%
Upside
Downgraded
09/16/25
Lucid Capital
$11→$1
Hold
1.01%
Upside
Downgraded
09/15/25
RBC Capital
$16→$1.5
Hold
51.52%
Upside
Downgraded
09/15/25
Cantor Fitzgerald
―
Hold
―
Downgraded
09/15/25
H.C. Wainwright
―
Hold
―
Downgraded
09/15/25
aTyr Pharma (ATYR) was downgraded to a Hold Rating at H.C. WainwrightValuation and Risks. We are downgrading the shares of aTyr to and removing our price target. We look to reassess our assessment of aTyr pending regulatory visibility about the overall status of efzofitimod, additional data, and any potential path forward. Factors that could impede the overall valuation of the company include failed or inconclusive clinical trials, the inability of the company to secure adequate funding to progress its drugs through the development pathway, the occurrence of dilutive capital raises, and lack of commercial success.
JonesTrading
―
Hold
―
Downgraded
09/15/25
Jefferies
$9→$17
Buy
1617.17%
Upside
Reiterated
08/22/25
Piper Sandler
$20
Buy
1920.20%
Upside
Reiterated
08/08/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$16→$1
Hold
1.01%
Upside
Downgraded
09/16/25
Wells Fargo
$25→$1
Hold
1.01%
Upside
Downgraded
09/16/25
Lucid Capital
$11→$1
Hold
1.01%
Upside
Downgraded
09/15/25
RBC Capital
$16→$1.5
Hold
51.52%
Upside
Downgraded
09/15/25
Cantor Fitzgerald
―
Hold
―
Downgraded
09/15/25
H.C. Wainwright
―
Hold
―
Downgraded
09/15/25
aTyr Pharma (ATYR) was downgraded to a Hold Rating at H.C. WainwrightValuation and Risks. We are downgrading the shares of aTyr to and removing our price target. We look to reassess our assessment of aTyr pending regulatory visibility about the overall status of efzofitimod, additional data, and any potential path forward. Factors that could impede the overall valuation of the company include failed or inconclusive clinical trials, the inability of the company to secure adequate funding to progress its drugs through the development pathway, the occurrence of dilutive capital raises, and lack of commercial success.
JonesTrading
―
Hold
―
Downgraded
09/15/25
Jefferies
$9→$17
Buy
1617.17%
Upside
Reiterated
08/22/25
Piper Sandler
$20
Buy
1920.20%
Upside
Reiterated
08/08/25
Best Analysts Covering aTyr Pharma
1 Month
xxx
Success Rate
5/12 ratings generated profit
Average Return
+2.01%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 41.67% of your transactions generating a profit, with an average return of +2.01% per trade.
3 Months
xxx
Success Rate
7/12 ratings generated profit
Average Return
+11.81%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +11.81% per trade.
1 Year
Success Rate
5/12 ratings generated profit
Average Return
-2.11%
reiterated a buy rating 2 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -2.11% per trade.
2 Years
xxx
Success Rate
1/12 ratings generated profit
Average Return
-34.98%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 8.33% of your transactions generating a profit, with an average return of -34.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ATYR Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
20
18
22
22
14
Buy
3
2
1
3
3
Hold
7
6
10
8
14
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
30
26
33
33
32
Each month's total comprises the sum of three months' worth of ratings.
ATYR Financial Forecast
ATYR Stock Forecast FAQ
What is ATYR’s average 12-month price target, according to analysts?
Based on analyst ratings, Atyr Pharma Inc.’s 12-month average price target is 6.92.
What is ATYR’s upside potential, based on the analysts’ average price target?
Atyr Pharma Inc. has 598.99% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ATYR a Buy, Sell or Hold?
Atyr Pharma Inc. has a consensus rating of Hold which is based on 2 buy ratings, 7 hold ratings and 0 sell ratings.
What is Atyr Pharma Inc.’s price target?
The average price target for Atyr Pharma Inc. is 6.92. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $1.00. The average price target represents 598.99% Increase from the current price of $0.99.
The highest analyst price target is $20.00 ,the lowest forecast is $1.00. The average price target represents 598.99% Increase from the current price of $0.99.
What do analysts say about Atyr Pharma Inc.?
Atyr Pharma Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of ATYR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.